ERBB2 and breast cancer: For the 8067 breast cancer patients, 60.5% (n = 4881) were classified as luminal A, 16.1% (n = 1296) as luminal B, 16.4% (n = 1327) as HER2‐enriched, and 7.0% (n = 563) as basal‐like breast cancer.